Utility
of
plasma
tumor
marker
levels
in
management
of
patients
with
Title ofappendiceal
the Poster adenocarcinoma
Presentation Goes Here
Authors of the Poster Presentation
Goes 1Here
1

Abdelrahman M. Yousef , Aditya More , Mohammad Zeineddine1, Saikat Chowdhury1, Yue Gu1, Julia Dansby1, Zahra Alavi Naini1, Abhineet Uppal1, Kanwal

Institutional and/or Graduate School of Biomedical Sciences Affiliation Goes Here
Raghav1, Michael J. Overman1, Keith Fournier1, John Paul Shen1
1The

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Background
•

Due to the rarity of appendiceal adenocarcinomas
(AA), systematic study of these tumors has been
limited. Thus, guidelines for the diagnosis and
treatment of AA are often based on other related
tumor types such as colorectal cancer

•

However, given that AA has been shown to be
molecularly and functionally distinct, there is a need
for focused clinical data to guide disease
management

•

In AA, tumor marker levels are used by some
practitioners to monitor response to treatment and
aid in diagnosis. This study evaluates the association
of elevated tumor marker levels with survival
outcomes

Results
Elevated CEA was predictive of overall survival in all
patients with median survival not-yet-reached for those
with normal CEA, not-yet-reached for those with elevated
CEA (HR: 3.7, p < 0.0001) and 99.8 months for those with
highly elevated CEA (101 ng/ml; more than 90th percentile
of CEA level) (HR: 9.0, p < 0.0001)

•

•

Given that tumor grade is the primary driver of prognosis
in AA, This analysis was repeated while controlling for
tumor grade

•

•

Elevated levels of CEA was strongly predictive of overall
survival for patients with low-grade tumors (HR: 19.3, 59,
respectively, p < 0.0001 for each) & high grade (HR: 2.9,
6.6, respectively, p < 0.0001 for each)

•

•
•

•

•

The MDACC database was queried to identify patients
with AA between 1997 to 2022
Patients with reported values for the tumor markers
CEA (n=1228), CA 19-9 (n=1042), and CA-125 (n=1067)
were then selected for analysis
Elevation of tumor markers was defined as above the
laboratory upper limit of normal (CA-125 > 37 U/mL,
CA 19-9 > 37 U/mL, and CEA > 3 ng/mL and survival
outcomes were compared with a log-rank (MantelCox) test
This analysis was repeated while controlling for
tumor grade, which was defined by low-grade: well,
well to moderately differentiated and high-grade:
moderate, moderate to poor, and poorly differentiated
Mutational profile was available for 334 patients, and
was analyzed to check for association with tumor
marker levels

Elevated levels of CA 125 was strongly predictive of
overall survival for patients with low-grade tumors (HR:
5.2, 8.7, respectively, p < 0.0001 for each) & high grade
(HR: 4.9, 8, respectively, p < 0.0001 for each)

Fig 2. Tumor marker levels distribution

Fig 3. KM plots for all patients
with normal, elevated and
highly elevated CEA and
patients spitted by tumor grade,
given that tumor grade is the
primary driver of prognosis in
AA

Fig 6. Heatmap plot considering gene mutations of all patients and how they
align with CEA, CA125, CA199 levels (n=334)
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•

Fig 1. MDACC Appendiceal Adenocarcinoma patients distribution by year

Fig 5. KM plots for all patients
with normal, elevated and
highly elevated CA19-9 and
patients spitted by tumor grade,
given that tumor grade is the
primary driver of prognosis in
AA

Fig 4. KM plots for all patients
with normal, elevated and
highly elevated CA125 and
patients spitted by tumor grade,
given that tumor grade is the
primary driver of prognosis in
AA

Patients and Methods
•

Elevated CA 125 was predictive of overall survival in all
patients with median survival not-yet-reached for those
with normal CA 125, 99.8 months for those with elevated
CA 125 (HR: 4.7, p < 0.0001) and 69.8 months for those
with highly elevated CA 125 (98 U/mL; more than 90th
percentile of CA 125 level) (HR: 8.3, p < 0.0001)

Elevated CA19-9 was predictive of overall survival in all
patients with median survival not-yet-reached for those
with normal CA19-9, not-yet-reached for those with
elevated CA19-9 (HR: 2, p = 0.0008) and 105 months for
those with highly elevated CA19-9 (338 U/mL; more than
90th percentile of CA19-9 level) (HR: 4.7, p < 0.0001)
Elevated levels of CA19-9 was strongly predictive of
overall survival for patients with low-grade tumors (HR: 7,
22, respectively, p < 0.0001 for each) & high grade (HR:
1.6, 2.7, respectively, p =0.09, p=0.0003 respectively )
A Logistic regression analysis model was built for the
mutational profiles using 334 patients’ mutational
analysis data, However, no statistical significance were
found for both univariate and multivariate analysis
between normal and elevated levels of tumor marker
levels

Conclusions
•

In summary, these data from a retrospective analysis
highlight the utility of using tumor marker levels in
conjunction with tumor grade to more accurately
predict prognosis in appendiceal adenocarcinoma
patients
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